With the development of a National Cancer Plan published in 2012, Germany has followed the recommendations of the WHO and the EU. The first area of action listed in Germanyʼs National Cancer Plan is improving the early detection of cancer. Both citizens and medical specialists are encouraged to take responsibility themselves and contribute to the efforts being made to meet the challenge of cancer. Screening for cervical cancer has long been an integral part of the German Directive for the Early Detection of Cancer and nowfollowing the recommendations given in the European Guidelinean organised screening approach shall be developed to maximise the benefits and minimise the risks through a partial reorganisation of existing structures. Before this can be rolled out nationwide, it will be necessary to check the feasibility and suitability of new contents and organisational structures. The Federal Joint Committee which is largely responsible for the process according to the draft law on the implementation of the National Cancer Plan has emphasised the importance of evidence-based medicine and of collaboration between the autonomous governing bodies within the healthcare system to obtain viable results. For medical specialists, the follow-on question is which areas will need more research in future. New process steps need to be developed and verified to see whether they offer evidence which will support defined approaches or whether such evidence needs to be newly compiled, e.g. by testing invitation procedures for screening in trial schemes. The experience gained during the implementation of the existing directive on early detection of cancer should be integrated into the new process. Research initiated by specialists could encourage the development of a new version of the Directive for the Early Detection of Cancer suitable for the Germanyʼs Background and Introduction ! In the last few years countries all over the world have developed national cancer plans. All of these plans were based on the recommendation issued by the WHO on the importance of developing "national cancer control programmes" [1] . Since 2008 various panels of experts have come together to work on a plan for Germany. The first National Cancer Plan for Germany was published in 2012. Now the contents need to be implemented. The framework policies need to be defined in law. The first ministry draft (Law on the Implementation of the Cancer Plan) was published in July 2012, and the governmentʼs draft legislation of a "law to promote the development of early cancer recognition and quality assurance through clinical cancer registries" (Cancer Early Detection and Cancer Registries Act, [Krebsfrüherkennungs-und -registergesetz] KFRG) was passed on August 22, 2012 [2] . In December 2012 the first hearing was held in front of the Health Commission of the German Federal Parliament. The draft is currently being reviewed in parliament. Numerous comments by various autonomous governing bodies within the healthcare system, by the Federal Medical Association and by other interested parties have since been published, highlighting various areas where opinions diverge, the range of opinions but also those areas where a consensus could be reached.
One of the areas about which there was a general consensus was the amendment to certain passages in § 62 SGB V1 [Volume V of the German Social Security Code]. In the new version, early detection and compliance are no longer linked to the receipt of benefits from statutory health insurance companies; early detection of cancer is now the individual responsibility and personal choice of each citizen. The text of the draft of the KFRG reads: "… Therefore the decision of individuals to avail themselves should be guided only by sufficient, comprehensible, neutral information and counselling and by the individualʼs personal values and preferences and should not be influenced by incentive schemes. This corresponds to recommendations made by the Council of Europe, by the European Guidelines and by experts for the National Cancer Plan, which give priority to independent, voluntary and informed decisions regarding participation" [2] . The National Cancer Plan has made promoting health literacy a core concern: all citizens should be encouraged to take personal responsibility for participating in the national effort to deal with the challenge of cancer (as documented in the Federal Health Report [3] ), and this new approach is visible in all sectors of the National Cancer Plan. Healthcare experts are similarly called upon to collaborate and contribute.
With regard to its practical implementation, the National Cancer Plan will affect those medical specialists working in areas of action where changes are planned. In gynaecology, the organisation of cervical cancer screening will be affected. 1 What is the National Cancer Plan? ! With the development of a National Cancer Plan, Germany followed the recommendations of the WHO and the EU (most recently, the conclusions of the EU Council dated 9/10 June 2008). The recommendations were fuelled by the increasing demands with regard to patient care, the increased complexity and specialisation in medicine; the necessity to improve education, training and advanced training; the need to improve interdisciplinary cooperation, quality assurance, evidence-based medicine, and patient orientation and, not least, the tendency referred to as the "chronification" of cancer. The German term "Nationaler Krebsplan" follows the commonly used international terminology (National Cancer Plan). In summary, the National Cancer Plan is a coordination and co-operation programme with a long-term perspective.
The German National Cancer Plan outlines four main areas of action and lists a number of goals: 1. Improve the early detection of cancer (Goals 1-3) 2. Improve the structure of oncological care, quality assurance and quality improvement (Goals 5-9) 3. Ensure efficient oncological treatment (with an initial focus on the provision of oncological drugs) (Goal 10) 4. Strengthen patient orientation (Goals 11-13) Goal 2a "Organised cervical cancer screening" in area of action 1: "Improve the early detection of cancer" aims to reorganise cervical cancer screening in Germany.
Legislation on the Implementation of the National Cancer Plan ! The implementation of the National Cancer Plan will be codified in law. The governmentʼs draft legislation dated August 2012 formulated a conceptual framework together with a number of measures outlined below "with regard to improving the early detection of cancer": " The maximum number of times persons can demand cancer screening and the age limits for cancer screening will no longer be mandated in law; instead, in future they will be determined by the Federal Joint Committee (Gemeinsamer Bundesausschuss [G-BA]) based on the current state of medical knowledge. " Cancer screening procedures already covered by an existing European guideline (published by the European Commission) on quality assurance for this cancer screening programme should be carried out as organised cancer screening programmes. Currentlyin addition to the established programme of mammography screeningthis applies to screening for cervical cancer and for bowel cancer. " The G-BA has the duty … to decide on the contents and organisational structure of organised cancer screening programmes for cervical cancer and bowel cancer which will take account of the relevant European guidelines. The Committee will additionally be given the possibility to verify the appropriateness of various contents and organisational structures of organised cancer screening programmes. …
Many of these aspects are currently being reviewed and discussed. In all cases, the Federal Joint Committee (G-BA) will play a key role in formulating requirements. The G-BA is the highest decision-making body for the autonomous governing bodies of physicians, dentists, psychotherapist, hospitals and health insurance companies in Germany. In its guidelines, the G-BA decides on the catalogue of benefits provided by statutory health insurance to more than 70 million insured persons in Germany and thus determines which healthcare benefits and services will be reimbursed in statutory healthcare. In addition, the G-BA decides on quality assurance measures for outpatient and inpatient healthcare [4] . The draft bill mentioned above also clarifies the specific steps needed to implement an objective, for example for the area of action 1 "Improve the early detection of cancer": "the goal is to provide better information about the benefits and risks of cancer screening … and make existing screening for cervical cancer and bowel cancer more effective by improving the invitation procedure, quality assurance measures and the measurement of outcomes."
Goal 2a of Area of Action 1 of the National Cancer Plan: Reorganisation of Cervical Cancer Screening ! Early detection of cervical cancer has been an integral part of the Directive for the Early Detection of Cancer since many years and will now be developed further to take account of the European guideline. Intention of this reorganisation is to maximise the benefits of early detection and minimise the risks. This would involve the organisational development and partial reorganisation of the current cervical cancer early detection programme. The European guideline also lists certain elements characteristic for population-based organised screening programmes; they include precise regulations governing procedures, defined structures, an organisational team to support screening (e.g. on a regional basis), and a procedure to determine the burden of disease in the general population [5] . Cancer screening procedures already covered by an existing European guideline published by the European Commission should be made available in the form of organised screening programmes. Implementation of an "organised cancer screening programme" must therefore " include regular invitations to insured persons to attend screening, " provide detailed information to insured persons, " must take account of recommendations in the European guidelines with regard to the examination method used, the age limit, the intervals between screening, and the investigation of any abnormal findings, " must take account of the recommendations on quality assurance in European guidelines, and " ensure the systematic recording of results, monitor outcomes and the improvement of quality.
Thus, an organised screening programme will require regulations on procedures (screening policy), together with a team to implement the regulations, organise the provision of care, and ensure that quality assurance measures are in place as well as the necessary structures for quality control and evaluation. The questions which arise will then be: which elements need to be added to the statutory early detection programme currently existing in Germany, which elements need to be improved and developed further, and what they should look like in practice, in order for these programmes to fulfil the basic goal behind these changes: that of maximising benefits and minimising risks. Cancer Screening in Germany as Defined in the Guidelines of the G-BA ! The yardstick against which changes to screening concepts based on recommendations in the European guidelines should be measured is the extent to which these changes will reduce the burden of disease (mortality/incidence) and the potential for damage (false positive findings, over-diagnosis, over-treatment, lulling into a false sense of security because of false negative findings) and whether these changes will make healthcare in Germany more cost-effective. This means that at the very latest (if not before) when screening concepts are being amended, the G-BA must also examine which parts of the European guideline are suited to being incorporated or adapted for use in Germany. Before comprehensively implementing an organised screening programme in accordance with SGB V [Volume V of the German Social Security Code] § 25 Abs. 6 (as was suggested in the draft legislation), it will be necessary to examine the new contents and organisational structures, for example, the process used to invite persons to attend screening or the measures used for quality assurance, with regard to their feasibility, suitability, effectiveness and cost. A pilot study should be carried out prior to implementing any big changes to investigate the feasibility, effectiveness and cost. "Suitability" also includes examining and, if necessary, adapting requirements of the European guideline to the patient care conditions in Germany. In the current draft legislation, the Federal Joint Committee (G-BA) is responsible for "drawing up a directive which will define the content, data flow, reimbursement and scientific evaluation of a feasibility study." Consequently, the draft legislation envisages the possibility of a trial scheme to test newly developed elements of an organised cancer screening programme. If the Federal Joint Committee concludes that the necessary information regarding the appropriate content and organisation of an organised cancer screening programme is not yet available, for example with regard to the best way of inviting persons for screening, it can draw up a directive for a trial scheme in accordance with § 137e SGB V (Trials of research methods and methods of treatment) to obtain the findings necessary to develop the content matter and organisation of a new screening programme. The time required to prepare, implement and evaluate the trial scheme should not exceed a period of 5 years. The G-BA being the prime actor, will include the autonomous governing bodies of the German healthcare system represented in the Joint Federal Committee. The G-BA has emphasised the importance of evidence-based medicine as the basis for action and stated that co-operation between the various autonomous governing bodies of the healthcare system is indispensable to obtain viable results. The advisory opinion of the G-BA given in the hearing on July 24, 2012 states: "besides, the task of improving early cancer detection in Germany can only be resolved in practice by the affected autonomous governing bodies of the healthcare system. The responsibility for fleshing out the possible scope of action must therefore rightly lie with the autonomous governing bodies. The existing commitment to evidence-based medicine as the yardstick for content thus complies with the requirements of constitutional law". [6] For Germany the initial focus on content will presumably be in the areas of action listed below. All of these areas will require the participation of and contributions by the autonomous governing bodies of the German healthcare system (the respective representatives of the bodies representing physicians with their own practice, hospitals and health insurance companies but also other bodies represented in the G-BA). Areas of action include " the procedure used to invite persons for screening, a procedure hitherto not regulated for the general population " the detailed information to be provided to persons invited for screening (hitherto not centrally specified) " the evaluation of individual procedural steps and the comparison of these steps with the recommendations given in the European guidelines (reasons for diverging from the European guidelines need to be stated and justified, and these reasons must be comprehensible; the suitability of amendments to optimise currently existing procedures in Germany must also be documented.) " a revision of the quality concept " transparency regarding quality " integration of procedures in an organisation concept ("screening policy")
An organised screening programme for cervical cancer is a multistage process with a succession of process steps which build on one another [21, 22] . The success of any subsequent step also depends on the appropriateness (with respect to concept, organisation and implementation) of the preceding steps.
For gynaecology, the question which follows on from that is the question regarding which areas will need more research in future.
The process steps developed for a screening programme must be evaluated to see whether there is clear evidence which supports an already existing established mode of approach (national/international) or whether the approach still needs to be developed further.
(The transferability of results from other countries which have other screening conditions must be considered separately; nevertheless, proposals for different concepts, strategic considerations and "lessons learnt" need to be taken into account.) This includes, among other things, " identifying the target population (Who? When? How often?) [7, 8] " the implications of introducing of HPV vaccination " the procedure for inviting women for screening and providing information to women entitled to screening " the administration of the Pap test " the findings of the Pap test and documentation of findings " informing women who have normal findings and the date of their follow-up examination [9] " summoning women with unusable findings for a repeat examination " the care of women with abnormal findings (diagnostics, treatment where required, a fail-safe system, but also a review of the problem of over-/under-treatment in women with CIN) [10] " the long-term consequences of false negative/false positive findings and subsequent interventions [11] " registration, monitoring and evaluation [12] A theoretical (research) and practical investigation of unanswered issues initiated by gynaecologists prior to the investigation of these issues by the various autonomous governing bodies could facilitate the process and even lead the way for a revision of the guideline on cancer screening. The key issues are those previously listed in the reports by the [16] aktualisiert. Die Kriterien zielen ab auf die Angemessenheit von Screening-Programmen und orientieren sich insbesondere daran, dass das Überwiegen des Nutzens belegt ist. Diese Bewertung hat physische und psychische Implikationen gleichermaßen einzubeziehen. Außerdem soll vorab geklärt sein, inwieweit die Einrichtungen und Ressourcen the beginning of 2012 on the value and role of various steps in a cervical cancer screening programme: the fact that studies which would shed more light on the benefits and risks are lacking. The precondition for any screening programme must be an investigation based on various criteriaas compiled for the first time in the WHO report "Principles and Practices of Screening for Diseases" published in 1968 [15] and updated in 2002 [16] . These criteria focus on the suitability of screening programmes and the necessity to prove that the benefits will outweigh the drawbacks. Evaluations must include both physical and psychological implications. It will be necessary to clarify in advance whether sufficient facilities and resources (expertise, staff, premises and financial means) are available to meet the demand for care, i.e. screening-associated activities and any consequent demands such as operative procedures, follow-up examinations, etc. The draft legislation cites the procedure used to invite women for screening as an example of an area where the new possibility of a trial scheme as outlined in § 137e SGB V (Trials of research methods and methods of treatment) could be used. For the German healthcare system, the experience gained out of the current early detection scheme will be very important when developing new regulations for screening trial schemes. Gynaecologists and other key policy makers have rightly pointed to various important successes achieved with the current guideline [17] . Only after the appropriate steps have been taken, including a systematic investigation [18] and trial schemes, will it be possible to summarise all the findings and create a new, appropriate and responsible organised screening programme (screening policy).
Conclusion

!
In the upcoming discussions on the design of an evidence-based screening programme, it is important to remember that, despite all measures taken to detect and prevent cancer, the priority must be to ensure that access to screening is low threshold and that screening is accessible to [19] and accepted by the target group [20] . Gynaecologists need to start by defining those areas which require more research prior to their implementation into a new version of the cancer screening guideline by the G-BA by considering the necessary steps of an organised screening and their course, also by rolling out trial schemes as outlined in § 137e SGB V. This would allow gynaecologists to offer proposals which meet with general consensus and to promote a process based on medical expertise which will offer solutions and amendments adapted to suit the German healthcare system. 
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